The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 09, 2016

Filed:

Dec. 20, 2013
Applicant:

Emory University, Atlanta, GA (US);

Inventors:

Harriet Robinson, Atlanta, GA (US);

James Smith, Cumming, GA (US);

Rama Amara, Atlanta, GA (US);

Bernard Moss, Bethesda, MD (US);

Salvatore T. Butera, Del Mar, CA (US);

Dennis Ellenberger, Norcross, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/21 (2006.01); C07K 14/005 (2006.01); C12N 15/70 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); A61K 39/39 (2006.01); A61K 39/12 (2006.01); A61K 49/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); C07K 14/005 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); C12N 2710/24143 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16222 (2013.01); C12N 2740/16234 (2013.01); C12N 2830/00 (2013.01); C12N 2830/15 (2013.01); C12N 2830/42 (2013.01); C12N 2830/60 (2013.01);
Abstract

We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).


Find Patent Forward Citations

Loading…